|March 12, 2014|
|09:45 EDT||ISIS, ISIS, BIIB, BIIB||Piper Jaffray's biotech analyst holds an analyst/industry conference call|
Analyst Schimmer discusses Isis Pharmaceuticals/Biogen's (ISIS/BIIB) SMNrx for Spinal Muscular Atrophy (SMA) on an Analyst/Industry conference call to be held on March 12 at 10 am.
News For ISIS;BIIB From The Last 14 Days
Check below for free stories on ISIS;BIIB the last two weeks.
|September 2, 2014|
|19:28 EDT||ISIS||Isis Pharmaceutical licensing partner Antisense reports ATL1103 phase II results|
Antisense Therapeutics, or ANP, reported the primary efficacy results from its phase II clinical trial of ATL1103 in patients with the potentially life threatening growth disorder, acromegaly. The phase II trial met its primary efficacy endpoint showing a statistically significant average reduction in the serum insulin-like growth factor-I, or sIGF-1, levels of 26% from baseline at week 14 at the 400mg per week dose tested. All patients treated with 400mg per week of ATL1103 had a reduction in sIGF-I levels from baseline at week 14. Greater reductions in sIGF-I were observed in patients who had lower body weights and thereby received a relatively higher dose per kg bodyweight with the patients who received 5.5 mg/kg per week showing a 36% average reduction in their sIGF-I levels. The positive results achieved in this Phase II trial position ATL1103 to move into Phase III stage of development. Consequently, ANP will accelerate out-licencing activities to secure a pharmaceutical development partner for the drug's further development. ANP has 4 products in its development pipeline that it has in-licensed from Isis Pharmaceuticals, including ATL1103.
|August 31, 2014|
|13:41 EDT||BIIB||Citigroup to hold a conference|
Subscribe for More Information
|August 28, 2014|
|07:05 EDT||ISIS||Isis Pharmaceuticals initiates ISIS-APOCIII Phase 3 study|
Subscribe for More Information
|August 27, 2014|
|09:08 EDT||BIIB||Nektar could see $100M in revenue from Baxter drug, says Roth Capital|
Roth Capital believes that Baxter's (BAX) BAX-855 drug delivered compelling Phase III data, and the firm expects the drug to compete effectively against Biogen's (BIIB) Eloctate. Roth expects BAX-855 to launch in 1Q16 and believes it could generate up to $100M in annual revenue for Nektar. The firm keeps a $21 price target and Buy rating on Nektar.
|08:21 EDT||BIIB||NICE recommends Tecfidera for multiple sclerosis|
Dimethyl fumarate is recommended as a possible treatment for people with active relapsing-remitting multiple sclerosis that isn't highly active or rapidly evolving severe relapsing-remitting multiple sclerosis, the U.K.'s National Institute for Health and Care Excellence stated in guidance posted to its website. Reference Link
|August 26, 2014|
|11:21 EDT||BIIB||Biogen added to short term buy list at Deutsche Bank|
|August 22, 2014|
|12:39 EDT||BIIB, ISIS||These five companies will benefit from increased ALS awareness, MarketWatch says|
A recent surge in funding for Lou Gehrig's disease, or ALS, caused by the Ice Bucket challenge that is widespread on social media outlets, will benefit five pharmaceutical companies that are involved in the development of a cure for ALS, according to MarketWatch. The companies that are or have been involved in developing a treatment for ALS include Biogen Idec (BIIB), Avanir Pharmaceuticals (AVNR), Isis Pharmaceuticals (ISIS), Sanofi (SNY), and Bristol-Myers Squibb (BMY), MarketWatch added. Reference Link